Mirabella Financial Services LLP Raises Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Mirabella Financial Services LLP grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 83.4% in the 3rd quarter, Holdings Channel reports. The firm owned 5,447 shares of the biopharmaceutical company’s stock after purchasing an additional 2,477 shares during the period. Mirabella Financial Services LLP’s holdings in Alnylam Pharmaceuticals were worth $2,479,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Groupama Asset Managment boosted its stake in shares of Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after purchasing an additional 2,483,697 shares in the last quarter. Norges Bank bought a new position in Alnylam Pharmaceuticals in the second quarter worth about $662,837,000. Arrowstreet Capital Limited Partnership lifted its holdings in Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after buying an additional 1,185,909 shares during the period. Qube Research & Technologies Ltd purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth about $369,943,000. Finally, Holocene Advisors LP bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $194,616,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ALNY shares. Needham & Company LLC decreased their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Chardan Capital decreased their price objective on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a report on Friday, February 13th. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Finally, Leerink Partners decreased their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $468.84.

Insider Buying and Selling

In related news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the sale, the executive vice president directly owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 9,577 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the sale, the chief executive officer owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. This represents a 10.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 53,923 shares of company stock valued at $18,072,087 over the last ninety days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $314.80 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $41.75 billion, a P/E ratio of 184.09 and a beta of 0.36. The stock’s 50 day moving average is $338.90 and its 200 day moving average is $406.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter in the previous year, the firm posted ($0.65) EPS. The firm’s quarterly revenue was up 84.9% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.